Published in Gene Therapy Weekly, April 23rd, 2009
“Omnia understands that much of the overhead associated with drug development requires the application of assets having high fixed and overhead costs,” said Dale VanderPutten, Ph.D., Chief Executive Officer of Omnia. “We have built our business model recognizing these costs are a strain for many firms. Outsourcing non-core activities reduces the risk drug developers face while allowing them to manage cash, contain costs, focus on core strengths, maintain...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.